1. Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, USA.
Semin Ophthalmol. 2021 May 19;36(4):224-231. doi: 10.1080/08820538.2021.1890793. Epub 2021 Feb 27.
Nerve growth factor (NGF), the prototypical neurotrophin first discovered in the 1950s, has recently garnered increased interest as a therapeutic agent promoting neuronal health and regeneration. After gaining orphan drug status within the last decade, NGF-related research and drug development has accelerated. The purpose of this article is to review the preclinical and clinical evidence of NGF in various applications, including central and peripheral nervous system, skin, and ophthalmic disorders. We focus on the ophthalmic applications including not only the FDA-approved indication of neurotrophic keratitis but also retinal disease and glaucoma. NGF represents a promising therapy whose therapeutic profile is evolving. The challenges related to this therapy are reviewed, along with possible solutions and future directions.
神经生长因子(NGF)是 20 世纪 50 年代首次发现的典型神经营养因子,最近作为一种促进神经元健康和再生的治疗药物引起了更多关注。在过去十年获得孤儿药地位后,NGF 相关的研究和药物开发加速。本文的目的是综述 NGF 在各种应用中的临床前和临床证据,包括中枢和周围神经系统、皮肤和眼科疾病。我们重点介绍眼科应用,不仅包括 FDA 批准的神经营养性角膜炎适应症,还包括视网膜疾病和青光眼。NGF 代表一种有前途的治疗方法,其治疗谱正在不断发展。本文还综述了与这种治疗相关的挑战,以及可能的解决方案和未来方向。